全球學名藥市場 ：主要企業分析・市場分析・市場預測（2007年至2012年・2017年・2022年）

全球學名藥市場 ：主要企業分析・市場分析・市場預測（2007年至2012年・2017年・2022年） 是由出版商Visiongain在2008年02月所出版的。 這份英文市場調查報告書包含320 pages 價格從美金2331起跳。

目錄

Abstract

The generic industry is a fast evolving market; with significant lucrative opportunities. The generic market is structurally set to experience high growth potential. That wave is partly driven by cost-containment in several national healthcare sectors and partly by the need for governments to promote the use of generic products over high-priced originator products without compromising quality.

In 2006, the global generics market attained strong revenues of approximately $65bn, up by 12% in comparison with $58bn in 2005. However, during the same period, the Top Ten leading generic suppliers generated total revenues of $27.9bn, up by a growth rate of 34%. The Top Five Companies within that sector experienced significant revenues, with market growth largely driven by significant commercial activities, key Mergers and Acquisition (M&A) and launch of new product in the leading markets.

In light, of the significant number of proprietary branded pharmaceuticals approaching patent expiration in the near-term, visiongain predicts that the generic market is set to experience further market expansion during the forecast period. Visiongain also predicts that by 2023, the Top Ten leading generic suppliers will experience CAGR of 7%. That significant CAGR, will be driven by generic versions of leading blockbuster drugs presently estimated at $100bn, nearing patent expiration during 2008-2012.

Prominently, amongst the products with looming patent expirations are drugs such as:

• Pfizer' s Lipitor
• AstraZeneca' s Nexium
• Bristol Myers Squib' s Plavix
• Pfizer' s Norvasc
• Lilly' s Zyprexa
• Janssen' s Risperdal
• Wyeth' s Effexor

In 2007, a total of 14 drugs came of patent in the US market. In 2008, a total of 14 drugs are expected to lose patent protection in the US market. In 2009, five drugs are predicted to becoming off-patent in the US market. On the 24 of March 2010, the world' s highest selling drug, Pfizer' s Liptor will come off-patent in the US. In the EU market, UCB' s Keppra and four other medicines are expected to lose patent protection. In 2011, 10 major drugs in the US market will also become exposed to generic competition. An estimated 11 drugs will experience generic competition in the EU market during the same year. Significant among these drugs will be Lipitor and Zyprexa.

Moreover, the generic market is projected to further expand through the growing uptake of biogeneric/ biosimilar products. In 2006, biological drugs, the products of biotechnology generated total revenues of $40bn. The US market alone, accounted for a significant proportion of total worldwide sales. Presently, in the EU, the growing popularity of these products are gaining newer heights, with managed care organisations (MCOs), healthcare providers and payers amongst others increasingly requesting these medicines as a significant cost-saving strategy. However, by 2010, an estimated 24 biologic drugs will near patent expiration opening up the market for generic possibilities.

Visiongain' s market analysis forecast a-to- be lucrative era during the mid-term of our forecast where we believe, the Top Ten generic suppliers will see strong sales growth leveraged through licensing of new products.

With Top Ten company-by-company forecast focus on regions:

• Asia
  • Teva (Asia/ Israel)
• Europe
  • Actavis (Finland)
  • Merck KGaA (Germany)
  • Ratiopharm (Germany)
  • Sandoz (Switzerland)
  • Stada (Germany)
• North America
  • Apotex (Canada)
  • Barr (US)
  • Mylan (US)
  • Watson (US)

This report includes detailed five-year forecasts over the period 2007-2012, and NOW features 10 and 15-year forecasts to help you understand the medium-term prospects for these markets.

Why You Must Buy This Report:

This report features in-depth primary research, tables, graphs and charts, news, insights, the past and present developments in Market. This report will provide you with the complete understanding of operations of Top Ten companies that has driven their corporate growth in recent times. In addition, the report sheds significant emphasis on key strategies that will drive year-on-year sales growth of their leading products. Despite the lucrative opportunities presented to the leading companies through patent expirations, the visiongain reports analyses the key battles that the leading Top Ten generic companies will face during the same period.

This visiongain report is the single tool to equip you with the latest trends in all regional markets and why all (stakeholders) are opting for cheaper generic medicine, that are equally potent as their originator versions. Visiongain recommends this astute report to the major players in the field as it will arm you with the major legal challenges that leading companies face to date. The report, will also inform you on how the Top Ten generic companies are positioning themselves in facing the rising inherent cost of R&D expenditure especially on difficult-to-manufacture biogeneric/ biosimilars. In addition, the reports present a 360 degrees overview of requirements set by major regulatory authorities for larger evidence of clinical data before any authorisation.

When you buy this report, you will also get an understanding, through our overview; of how present changes in Governmental Pharmaceutical Policies with respect to cost-cutting coupled with major hurdles by that the Top Ten generic suppliers will have to overcome in the growing presence of price erosion /sensitivity in key and emerging markets. The Top Ten Generic League Market Analysis & Forecasts 2007-2023 report is a must buy, because it presents in-depth and unbiased financial analysis for the near-term, medium-term and the long-term, market dynamics.

When you buy the Visiongain 2008 Top Ten Generic League report, you will be buying current and vital information on the vast array of commercial opportunities marked for potential success in the long-term treatment of the generic market.

Unique benefits to you when you order this report:

• - Primary research throughout. You will not find this information anywhere else
• - Report stored in your reading room for ever
• - Full searchable report when you buy the company or corporate editions
• - Copies can be printed off for offline reading
• - Packed with charts, analysis, figures, graphs and tables

What questions does the report answer?

• Who are the generic market leaders?
• Which regions dominate the generic market?
• Which of the Top Ten companies conducted key M&As to bolster product pipeline?
• Have the M&As been successful in expanding product range?
• Is the cost of branded medicines justifiable by Big Pharma?
• How will the Top Ten account for future revenues?
• Will the Top Ten continue to experience market share expansion?
• How will the Top Ten overcome the legal battles?
• Are the legal battles really worth the cost of the generic medicines?
• What direction is Biogenerics marketing taking?
• Will the EU regulatory bodies narrow the generic gap between the US?
• Will the Top Ten themselves be acquired under mounting pressure of strong market competitions?
• Will the rising cost of R&D, deter the Top Ten from investing?
• Are the voices of managed care organisations (MCOs), healthcare providers and payers driving down sales of Big Pharm' s blockbusters?
• Is the EU a "nice-to-operate-in" or a "must-operate-in" market for the Top Ten?

Table of Contents

1. Executive Summary

2. An Overview of The Leading Generics Producers in 2007

• 2.1 Generics Medicines Experience Significant Growth in 2006
• 2.2 Teva Records Largest Sales of Generic Pharmaceuticals Globally in 2006

3 The World Generics Market

• 3.1 The World Generics Market to Grow by over 12% Per Annum to 2010
• 3.2 Top 20 Companies To Lose Leading Products To Generic Competition
• 3.3 Price is the Principal Competing Factor in the Generics Market
• 3.4 Countries with Lowest Branded Drug Prices have the Highest Generic Growth
• 3.5 Patent Expiration is the Major Driver in All Generic Markets
• 3.6 The US Has The Largest Generics Market
• 3.7 The UK has the Highest Generic Penetration by Value in All European Markets
• 3.8 Japan An Isolated Case in the Generic Market

4. The US and European Regulation of Generic Drugs

• 4.1 Generic Pharmaceuticals in the US Market
  • 4.2.1 The Hatch-Waxman Title I,
    • 4.2.1.1 US Congress First To Market 180-Day Exclusivity Period Incentive
    • 4.2.1.2 Bioequivalence An FDA Requirement
• 4.3 The Hatch-Waxman Act Title II has Promoted Innovation in the Branded Pharmaceutical Industry
• 4.4 The Hatch-Waxman Act Drives Influx Of Generic Pharmacuticals Significantly
• 4.5 Marked Difference In European Generics Patents Laws In Comparison With The US
• 4.6 European Generic Drug Development: Variation Between European Countries
• 4.7 EU Benefits From Long Data Exclusivity Protecting Patents
• 4.8 Additional EU Patent Protection is Afforded by Supplementary Protection Certificates
• 4.9 Compulsory Licensing Allows Generic Manufacture Before Patent Expiry
• 4.10 The WHO and Compulsory Licenses
• 4.11 Compulsory Licenses and the TRIPs Agreement
• 4.12 The Benefit of Being the First Generic to Market
• 4.12 The Advatages of First-to-Market Generics
• 4.13 Biogenerics A Continuously Expanding Market
• 4.14 Bioequivalence A Growing Concern For The Biogenerics Industry
• 4.15 US Biogenerics Regulatory Framework Awaits The Implementation of New Bills
• 4.16 European Drug Regulation Framework
• 4.17 European Medicines Agency (EMEA) Amends Its Biogeneric Regulation

5 TEVA Pharmaceutical Industries

• 5.1 Teva is Listed on Various Stock Exchanges, Including NASDAQ
• 5.2 Teva Achieved Sales of $8.4bn in 2006
  • 5.2.1 Most of Teva' s Sales are In North America
  • 5.2.2 Most of Teva' s Sales Are Generated by the Pharmaceuticals Division
  • 5.2.3 Vision and Core Values in Teva
• 5.3 Human Pharmaceuticals Division
  • 5.3.1 Teva Produces Generic Drugs in All Major Therapeutic Categories
  • 5.3.2 Teva Markets and Develops Innovative Drugs for Specialised Markets
  • 5.3.3 The Pharmaceuticals Division Contributes 90% of Teva' s Revenues
  • 5.3.4 Copaxone (glatiramer acetate)
  • 5.3.5 Azilect (rasagiline)
• 5.4 Active Pharmaceutical Ingredients (API) Division
• 5.5 Teva USA
• 5.6 Veterinary Products
• 5.7 Key Acquisitions by Teva
  • 5.7.1 Acquisition of Ivax Corporation in January 2006
  • 5.7.2 Sicor became a wholly owned subsidiary of Teva in January 2004
  • 5.7.3 Acquisition of Novopharm
• 5.8 A Brief History of Teva
  • 5.8.1 Formation of the Company at the Start of the Twentieth Century
  • 5.8.2 Growth During the WWII and the Establishment of the State of Israel during 1940s & 50s
  • 5.8.3 Consolidation During the 1960s & 70s Establishment of Teva Pharmaceutical Industries Ltd
  • 5.8.4 Further Acquisitions and Dominance During the 1980s
  • 5.8.5 1990s: Expanding Presence Worldwide
• 5.9 Teva Benefited from an Ambitious Strategy of Acquisition
• 5.10 Teva Had Over 150 Products Awaiting FDA Approval at the End of 2006
• 5.11 Promising First Quarter Results for 2007
• 5.12 Copaxone - Teva' s First Innovative Drug to Receive FDA Approval
• 5.12 Copaxone - Teva' s First Innovative Drug to Receive FDA Approval
  • 5.12.1 Steady Revenue Increase Expected for Teva' s Flagship Product
    • 5.12.1.1 Copaxone A Unique Immunomodulator Therapy For The Treatment of Relapsing-Remitting Multiple Sclerosis.
  • 5.12.2 Copaxone Faces Present and Future Competitive Challenges in the Market
  • 5.12.3 Copaxone Was Originally Licensed from the Weizmann Institute of Science
  • 5.12.4 Copaxone is the Subject of Promising Clinical Studies
  • 5.12.5 Lifecycle Management of Copaxone: Teva Makes Good Use of Collaborations
• 5.13 Azilect - Teva' s Recently Launched Innovative Product
  • 5.13 1 Azilect is Currently In a Period of High Early Growth
  • 5.13.2 Azilect is a Potent Agent for Early and Advanced Parkinson' s Disease
  • 5.13.3 Azilect Benefits from Convenient Dosing
  • 5.13 4 Azilect is Co-Marketed in Europe by Lundbeck and Teva
  • 5.13.5 Co-Development of Azilect with Eisai
  • 5.13.6 Phase IV Post-Marketing Study to Investigate Risk of Melanoma
  • 5.13.7 Azilect May Have Potential in the Early Treatment of Parkinson' s
  • 5.13.8 Competition for Azilect
  • 5.13.9 Azilect Has Performed Well in Clinical Studies
• 5.14 Teva Has a Diverse Generics Portfolio
  • 5.14.1 Revenues from Generics Spread Over Many Products
  • 5.14.2 Teva Receives First US Approval For Generic Uniretic Tablets
  • 5.14.3 Teva Receives Approval For Generic Dostinex Tablets
  • 5.15.4 Teva Announced Approval of Alprazolam ER Tablets
  • 5.14.5 Teva Announced Its Launch of Generic Wellbutrin XL Tablets Through Agreement With Anchen And IMPAX
  • 5.14.6 Teva Announced Tentative Approval Of Sumatriptan Succinate Tablets
  • 5.14.7 Teva Receives Approval for Generic Focalin Tablets
  • 5.14.8 Teva Announced Agreement with Pfizer Regarding Idarubicin, Azithromycin, And Epirubicin
  • 5.14.9 Launch of Generic Zoloft by Teva
  • 5.14.10 Final Approval of Venlafaxine HCL Tablets
  • 5.14.11 Final Approval of Meloxicam Tablets
  • 5.14.12 Tentative Approval of Generic Lotrel
  • 5.14.13 Approval of Generic Zocor
  • 5.14.14 Teva Received First FDA Approval for Generic Proscar Tablets
  • 5.14.15 Tentative Approval of Losartan Potassium & Hydrochlorothiazide Tablets
  • 5.14.16 Tentative Approval for Generic Cozaar Tablets
  • 5.14.17 Tentative Approval of Simvastatin Tablets
  • 5.14.18 Approval of Generic Lexapro Tablets
• 5.15 The Integration of Ivax' s Operations Greatly Increased Teva' s Strengths in Respiratory Drugs
• 5.16 Teva Pharmaceutical Market Forecast 2008-2013 & 2023
• 5.17 Pipeline Developments in Teva
  • 5.17 1 Teva is Conducting R&D in Important Therapeutic Areas
  • 5.17.2 Teva' s Investment in R&D Has Been Rising in Recent Years
  • 5.17.3 As a Leading Generic Producer Teva Has Progressed into Innovative Research & Development
• 5.18 Teva Has a Very Strong Generics Pipeline in Addition to Innovative Developments
  • 5.18.1 R&D Focussed on Multiple Sclerosis, Autoimmune Diseases, Neurology and Oncology
  • 5.18.2 Teva R&D is Concentrated in Four Divisions
• 5.19 Antineoplastics/Immunomodulating Agents
  • 5.19.1 Stemex Cell Therapy
  • 5.19.2 HMN 214
  • 5.19.3 EDRATIDE (TV 4710)
  • 5.19.4 SAIK-MS
  • 5.19.5 LMB 9
  • 5.19.6 Cervene (TP 38)
• 5.20 Central Nervous System Agents
  • 5.20.1 Citicoline (IP 302)
  • 5.20.2 Cladribine (NSC 105014F)
  • 5.20.3 Fampridine-SR
  • 5.20.4 Ladostigil
  • 5.20.5 Valrocemide
• 5.21 Genitourinary System/Sex Hormones
• 5.22 Respiratory System Agents
  • 5.22.1 Respicort
  • 5.22.2 Other Agents in Development
• 5.23 Licensing Deal With Vaccinex for Monoclonal Antibody
• 5.24 Teva Collaborates on Protalix' s Recombinant Plant Cell Expression Technology
• 5.25 Teva And Procognia (Israel) Ltd. Sign an Exclusive Collaboration Agreement for the Development of Biopharmaceuticals

6 Novartis' Sandoz

• 6.1 Sandoz is a Leading Supplier of Generics Internationally
  • 6.1.1 Sandoz Has A Wide Product Range An Important Core Competencies
  • 6.1.2 Sandoz Finally Benefits from Landmark Regulatory Decision Concerning Omnitrope
  • 6.1.3 Sandoz
• 6.2 Novartis' Sandoz Generics Division
  • 6.2.1 Background: Novartis Re-branded Its Generics Companies as Sandoz
• 6.3 Sandoz Has A Complex History From Establishment in 1886 to Present
• 6.4 Sandoz Has a Broad Product Range, Much of it Due to Acquisition of Generics Companies
• 6.5 Retail Generics Produces Finished Dosage Generic Forms
• 6.6 Sandoz Products: Retail Generics
• 6.7 Sandoz Products: Contract Biopharmaceuticals
• 6.8 Sandoz Products: Active Pharmaceutical Ingredients (API)
• 6.9 Sandoz Products: Product Intermediates
• 6.10 Sandoz Achieved Impressive Growth in 2006
• 6.11 Sandoz Will Achieve Strong Growth from 2008-2023
• 6.12 Sandoz Has Consolidated Its Market Position Through Acquisitions
  • 6.12.1 Sandoz Acquisition Post-Unification: Sabex
  • 6.12.2 Sandoz Acquisitions Post-Unification: Durascan
  • 6.12.3 Novartis Bought Hexal and Eon in $7bn Deal
• 6.13 Sandoz Receives Landmark US and European Regulatory Approval for Omnitrope in 2006
  • 6.13.1 Sandoz is Committed to The Emerging Field of Biosimilars - Generic Versions of Biopharmaceuticals
  • 6.13.2 Sandoz Filed Lawsuit Against FDA Ruling on Omnitrope
  • 6.13.3 Omnitrope Finally Received US and EU Approval in Early 2006
  • 6.13.4 Omnitrope is a Ground-Breaking Product in the Generics Sector - With Far Reaching Implications for the Market
• 6.14 Sandoz Invests in Low Cost Production
• 6.15 The Outlook 2008-2023- Being Part of Novartis Will Confer a Significant Competitive Advantage upon Sandoz
  • 6.15.1 Generics Market is Increasingly Competitive
  • 6.15.2 Sandoz Generic Segment Forecast 2008-2013 & 2023
  • 6.15.3 A Co-ordinated Strategy by Novartis Benefits Sandoz Greatly
  • 6.15.4 Sandoz Will Continue to Gain Prominence in the World Generics Market

7. Merck KGaA

• 7.1 Merck KGaA is a Leading International Producer of Generic Pharmaceuticals
  • 7.1.1 Merck - The Oldest Pharmaceutical Company in the World
  • 7.1.2 The Structure of the Merck KGaA
  • 7.1.3 The Generics Division Generates the Second Largest Sales in Merck' s Pharmaceuticals Business Sector
  • 7.1.4 Recent Developments in Merck Generics - Expansion of Core Business
• 7.2 Merck Generics Worldwide: the Merck KGaA group of companies
  • 7.2.1 Alphapharm - Australia
  • 7.2.2 Genpharm - Canada
  • 7.2.3 Merck South Africa
  • 7.2.4 Generics UK Limited
  • 7.2.5 Dey Incorporated
  • 7.2.6 Other Merck Companies Worldwide
• 7.3 Merck Generics Financials, 2006
  • 7.3.1 Merck Has Two Types of Generics Markets
  • 7.3.2 Generics Division Experiences The Highest Operating Results
  • 7.3.3 France Sees Generic Expansion
    • 7.3.3.1 Merck KGaA' s Spanish Market Experiences 47% Rise is Sales in 2006
  • 7.3.4 Merck KGaA Sales Declines in UK and Germany
  • 7.3.5 Integration of Dey as the Basis for Strategic Reorientation
  • 7.3.6 Sales Rise in The US and Canada
  • 7.3.7 Japan Experiences Sustained Revenue Growth
• 7.4 Merck KGaA Generics Segment Forecast, 2008-2013 & 2023
• 7.5 Merck Set to See Sustainable Generic Revenues Through Innovation of Product Life Cycle.
• 7.6 Major Developments in Merck Generics
  • 7.6.1 Innovative Products for High-Growth Indications
  • 7.6.2 Acquisition of NM Pharma from Pfizer
  • 7.6.3 Litigation and Other Claims Against Subsidiaries Resolved
  • 7.6.4 Merck To Leverage Its Position In Generic Respiratory Medicines
• 7.7 Merck' s Strategic Acquisition of Serono Will Drive Revenues in the Long-Term

8. Ratiopharm

• 8.1 Ratiopharm Is a Pioneer In Generics Pharmaceuticals
• 8.2 RatioPharm Generics Segment
• 8.3 International Sales Drives RatioPharm' s Revenue
• 8.4 Ratiopharm Leading Generics Sale
  • 8.4.1 Ratiopharm Regional Sales
  • 8.4.2 The US and Canadian Market
  • 8.4.3 Sales Distribution in Africa, Asia and Australian Markets, 2006
  • 8.4.3 Brazil Dominates Latin American Market
• 8.5 Ratiopharm Generic Segment Forecast 2008-2013 & 2023
• 8.6 Research And Development
  • 8.6.1 Ratiopharm Commences Biogeneric Projects
    • 8.6.1.1 Ratiopharm Enters Agreement With BioGeneriX and Neose
    • 8.6.1.2 Ratiopharm and Neose' s pegylated GCSF in Phase I Studies
• 8.7 Litigation and Agreements
  • 8.7.1 Ratiopharm Successfully Challenges Patent Protecting AstraZeneca' s Nexium (esomeprazole)
  • 8.7.2 Court Rules Against Ratiopharm' s Lipitor Challenge
• 8.8 Mergers and Acquisition
  • 8.8.1 Ratiopharm Acquires Magnafarma
  • 8.8.2 Ratiopharm Other Key Acquisitions

9 Watson Pharmaceuticals

• 9.1 History and Background to Watson Pharmaceuticals
• 9.2 Watson' s Generics Operations - A Large Product Portfolio Combined with A Strong Pipeline
• 9.3 Watson' s Strategy - The Development of Technologically Challenging and High Demand Products
• 9.4 Watson Business Strategy
• 9.5 Watson R&D Expenditure Expands
• 9.6 Watson' s Generic Product Range Accounts for Over Two Thirds of Net Sales
• 9.7 Watson' s Branded Products Profit Margins decline in 2006
• 9.8 Merger Between Watson and Andrx Drives Sales of Generic Products
• 9.9 Watson Generics Segment Forecast, 2008-2013 & 2023
• 9.10 Watson New Generic Product Launches
• 9.11 Watson Puerto Rico Site to Close as Cost Saving Strategy
• 9.12 Watson Agreements
  • 9.12.1 Agreement with GSK to Market Generic Zyban
  • 9.12.2 Agreement with Proctor & Gamble to Distribute Generic Macrobid
  • 9.12.3 Watson Terminates its Contract Sales Force Agreement With Ventiv Health
  • 9.12.4 Litigation Proceedings - Possible Adverse Effects on Company Finances
• 9.13. Watson Alliances and Collaborations
• 9.14 Watson' s Branded Pharmaceutical Will Contribute Significantly To Year-on-Year Sales Growth

10 Actavis

• 10.1 Actavis Leading European Generic Company
• 10.2 Actavis Products Portfolio And Strategic Business Markets
• 10.3 Actavis Market Segmentation Market Segmentation
  • 10.3.1. Actavis North American Markets Generates Highest Revenue
  • 10.3.2 Actavis CEEA Markets Performance
  • 10.3.3 Actavis WEMEA Markets
    • 10.3.3.1 Actavis Sales in The UK Grows By 6%
    • 10.3.3.2 Actavis Sales in Germany Declines
    • 10.3.3.3 Actavis Experiences Sales Declines in The Netherlands
    • 10.3.3.4 Actavis Scandanavian Market Grows
• 10.4 Actavis Third-Party Markets
• 10.5 Actavis Generics Segment Forecast, 2008-2013 & 2023
• 10.6 Actavis' Pipeline - Strong Product Development and Investment in Manufacturing
  • 10.6 1 Actavis' ANDA Filings Increases Significantly In Both US And EU
  • 10.6 2 Actavis Expands IP Project India and Iceland
  • 10.6 3 Actavis And Colotech Investigates Cancer Chemoprevention Medicines
• 10.7 Mergers, Acquisitions and Agreements
  • 10.7.1 Actavis Subsidiaries Expands
  • 10.7.2 Actavis Acquires Alpharma
  • 10.7.3 Actavis Establishes Global Hospital Business Unit (GHBU)
  • 10.7.4 Actavis To Expand In-licensing Deals
• 10.8 Actavis Is Strongly Positioned To Maintain Status As a Leading Generics Supplier

11. Barr Pharmaceuticals Inc

• 11.1 Barr Has Developed A Strong Range of Therapeutic Core Competencies
• 11.2 Barr' s Strengthens Portfolio Through Acquisition of Pliva
• 11.3 Barr Experiences Revenue Decline After Transition Period (July1-December 31)
• 11.4 Barr Products: Specialisation in Oral Contraception and HIV/AIDS
• 11.5 Barr Leading Products
• 11.6 Barr Key Financials
  • 11.6.1 Barr Generics Revenue
  • 11.6.2 Barr DDAVP (Desmopressin Acetate) 180 Days Marketing Exclusivity
  • 11.6.3 Barr Exclusive Provider of Diadanosine Delayed-Release Capsules.
  • 11.6.4 Court Denies Aventis Motion Against Barr' s Generic Allegra
  • 11.6.5 Barr Completes Isotrenioin Strength
  • 11.6.6 Barr Completes Claravis (Isotrenioin) Strength
  • 11.6.7 Barr Launches Leflunomide and Clonazepam Orally Disintegrating Tablets
• 11.7. Other Significant Barr Generic Launches
  • 11.7.1 Barr' s Aranelle Generic Version of Watson' s Tri-Norinyl
  • 11.7.2 Barr' s Kelnor Generic Version of Pfizer' s Demulen
  • 11.7.3 FDA Approves Barr' s Anagrelide Hydrochloride, Generic Version of Shire' s Agrylin
  • 11.7.4 Barr' s Duramed Expands Products With Shire' s Adderall IR
  • 11.7.5 Duramed To Market Seqsonique Extended-Cycle Oral Contraceptive In Leading Markets
  • 11.7.6 Barr Markets Generic Glucophage (metformin hydrochloride) For Diabetes
  • 11.7.7 Barr Investment In DTC Will Drive Products Growth
• 11.8 Pending Generic Patent Challenges
• 11.9 Barr Generics Segment Forecast, 2008-2013 & 2023
• 11.10. Proprietary Product Sales
  • 11.10.1 Barr' s ParaGard IU - A Non-Hormonal Contraceptive Proprietary Franchise
  • 11.10.2 Barr Doubles Women' s Health Sales Force
  • 11.10.3 Duramed' s Plan B OTC/Rx Emergency Contraceptive Receives Marketing Approval
  • 11.10.4 Duramed' s Proprietary Drugs Portfolio Boosted By Pliva Acquisition
• 11.11 Barr Invests Significantly in R&D of Generic And Proprietary Products
  • 11.11.1 Pliva Acquisition Strenghtens Barr R&D Pipeline Significantly
• 11.12 Barr' s Alliances
• 11.13 Litigations Facing Barr

12 Stada Healthcare

• 12.1 Stada A Leading European Generics Pharmaceutical Company
• 12.2 Stada Key Competencies
• 12.3 Stada Regional Sales
• 12.4 Stada US Markets Revenue Declines
  • 12.4.1 Stada Sales Reaches Newer Heights In The EU Market
  • 12.4.2 Stada' s Key EU Markets Contributes Significantly To Yearly Sales
• 12.5 Stada Generics Division
  • 12.5.1 Omeprazole - Stada' s Leading Product
• 12.6 Stada Branded Products
  • 12.6.1 Stada' s Proprietary Products Sales Growth Exceeds 20% In 2006
• 12.7 Stada Generics Segment Forecast, 2008-2013 & 2023
• 12.8 Stada Product Developments
• 12.9 Mergers, Acquisitions and Disposals
  • 12.9.1 Stada Acquires Significantly In 2007
• 12.10 Stada Initiates Biosimilar Projects
  • 12.10.1 Stada And Bioceuticals Arzneitmittel' s Biosimilar Pipeline.
  • 12.10.2 Stada Erythropoietin-Zeta (Epo-zeta)Receives Positive Opinion From EMEA

13. Mylan Laboratories

• 13.1 Mylan Was Originally a Packaging Company
• 13.2 Mylan Leading Therapeutic Classes
• 13.3 Mylan Records Highest Sale in US Market
  • 13.3.1 Mylan Product Sales Grows In the EU Market
• 13.4 Mylan' s Pharmaceuticals Product Porfolio Expands Significantly
• 13.5 Mylan' s Recent Financial Results
• 13.6 Mylan New Product Lauches To Drive Revenue Growth
  • 13.6.1 Mylan launched Amlodipine Besylate
  • 13.6.2 Mylan' s Oxybutynin ER Tablets
  • 13.6.3 Mylan' s Propranol hydrochloride ER capsules
  • 13.6.4 Mylan' s Other Major Launches
  • 13.6.5 Mylan Generics Segment Forecast, 2008-2013 & 2023
• 13.7 Mylan Increases R&D Expenditure
  • 13.7.1 Mylan Has A Strong Pipeline And Increased R&D Spending
• 13.8 Mergers, Acquisitions and Agreements
  • 13.8.1 Mylan Completes The Acquisition of Matrix Laboratory Outstanding Shares
  • 13.8.2 Mylan And Matrix Acquisition Will Intensify Antiretroviral Research
• 13.9 Legal Challenges on Products
  • 13.9.1 Omeprazole
  • 13.9.2 Lorazepam and Clorazepate

14. Apotex

• 14.1 Apotex Privately Owned Canadian Pharmaceutical Firm
• 14.2 Apotex Geneic Division
• 14.3 Apotex Experiences Continuous Growth Revenue
• 14.4 Apotex Regional Segmentation
  • 14.4.1 EU Region Apotex' s Third Largest Market
  • 14.4.2 Apotex' s Sales Growth Expands in Latin And Central American Markets
  • 14.4.3 Apotex' s Africa, Asia and Australia Generated The Least Sales In 2006
• 14.5 Apotex Leading Generic Drugs
  • 14.5.1 Sanofi-Aventis And BMS Secure Injunction Against Apotex' s Leading Drug Clopidogrel
  • 14.5.2 Apotex' s Omeprazole Sales Expands By A Significant Margin
• 14.6 Apotex Generics Segment Forecast, 2008-2013 & 2023
• 14.7 Apotex Research and Development
  • 14.7.1 Apotex R&D Investment Drives Sales By Over 20%
  • 14.7.2 Apotex R&D Projects Increases Innovative And Biotechnological Products
  • 14.7.3 Apotex Markets Amlodopine Generic Version of Pfizer' s Blockbuster Drug Norvasc
  • 14.7.4 Apotex Intensifies Haematology And Skin Replacement Research
• 14.8 Apotex Second Largest Mergers and Acquisitions
• 14.8.1 Apotex Acquires Lareq Pharma In Spain
• 14.9 Apotex Will Compete Strongly With The Top Five Leading Generic Companies

15. Conclusions

• 15.1 Generics Market Bubble-Patent Expiration $100bn Branded Products
• 15.2 Major Wave of Patent Expirations To Occur
  • 15.2.1 Patent expirations in 2006
  • 15.2.2 Patent Expirations in 2007
  • 15.2.3 Patent Expirations in 2008
  • 15.2.4 Patent Expirations in 2009
  • 15.2.5 Patent Expirations in 2010
  • 15.2.6 Patent Expirations in 2011
• 15.3 Generic Drugs Uptake in The US on the Rise
• 15.4 The UK has the Highest Generic Penetration by Value in All European Markets
• 15.5 The Expiration of Branded Patents is The Most Important Driver of Growth in The Sector
• 15.6 Characteristics of Differing Regulatory Systems Affect the Market for Generics
• 15.7 Biogenerics Are Becoming Increasingly Important
• 15.8 Teva Leads The Generic Sector
• 15.9 Consolidation to be Key Factor in Growth of Generic Industry
• 15.10 Strong Positioning in EU Market Will Be An Influential Factor For High Revenue
• 15.11 Generics Sector An Expanding Market With Lucrative Opportunities
• 15.12 Strategic Focus On Geographical Markets Will Be Key To Levarging Technological Innovations
• 15.13 Growing Presence of Automatic Substitution At Pharmacy Will Drive Generic Growth
• 15.14 Top Ten Generic Companies Will Experience Strong Revenues During 2008-2023
• 15.15 Device-Driven Products Holds Significant Revenue Potential For Generic Investors
• 15.16 Product Life-Cycle Management Will Be Crucial To Generic Revenue Growth

List of Tables

• Table 1.1 Top 10 Generic Comapnies, Generics Revenue ($bn) Forecast, 2008-2013,2018 & 2023
• Table 2.1 Sales of All Companies: Total Group and Generics Sales,2005-2006
• Table 2.2 Sales of All Companies: Total Group Sales,2005-2006
• Table 2.3 The Leading Generics Companies: Total Generic Sales Only, 2005-2006
• Table 3.1 Major Drugs Losing Patent Expiration in Near-Term
• Table 3.2 Branded and Generics Price Differentials in Selected Leading European Countries, 2006
• Table 3.3 The Top Ten US Generic Drugs by Revenue ($m) and Units
• Table.3.4 Prescription Number (m), 2004 Top 10 Generic Drugs, Dispensed by Prescriptions in the US, 2006
• Table 3.5 US Top Ten Generic Drugs as a Function of Combined Branded and Generic Drugs by Prescription Number (m) and Revenues ($m),2006
• Table 5.1 Top 20 Leading Pharmaceutical Companies,2006
• Table 5.2 Teva Net Sales, Net Income, 2006
• Table 5.3 Teva Subsidiaries, 2006
• Table 5.4 Sales ($m) by Geographical Area, 2004-2006
• Table 5.5 Sales ($m) by Business Division, 2004-2006
• Table 5.6 Principal Therapeutic Products Manufactured by Teva, 2007
• Table 5.7 Teva Pharmaceuticals: Top Five Therapeutic Classes, 2005-2006
• Table 5.8 Pharmaceuticals: Leading International Products, 2005-2006
• Table 5.9 Teva Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Table 5.10 R&D Investment by Teva, 2002-2006
• Table 5.11 Summary of R&D Pipeline
• Table 6.1 Sandoz Net Sales ($m) and Other Key Financials, 2006
• Table 6.2 Sandoz Net Sales (%) by Region, 2006
• Table 6.3 Sandoz Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Table 7.1 Sales of Pharmaceutical and Chemical Division, 2002-2006
• Table 7.2 Revenues of Pharmaceutical Businesses, 2002-2006
• Table 7.3 Merck KGaA Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Table 8.1 Revenues of Top Ten Selling Therapeutic Classes,2006
• Table 8.2 Revenues of Top Ten Selling Generics, 2006
• Table 8.3 Regional Sale Distribution, 2006
• Table 8.4 Sales Distribution in Major EU Markets, 2006
• Table 8.5 Sales Distribution in Canada and the US, 2006
• Table 8.6 Sales Distribution in Africa, Asia and Australian Markets, 2006
• Table 8.7 Sales Distribution in Latin and South American Markets, 2006
• Table 8.8 Ratiopharm Subsidiaries
• Table 8.9 Ratiopharm Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Table 9.1 Total Revenue including Major Operations, 2006
• Table 9.2 Net Revenue In Comparison With Other Operational Losses, 2006
• Table 9.3 Generic Segment Sales, 2006
• Table 9.4 Revenues of Branded Products Operations, 2006
• Table 9.5 R&D and Other Operating Expenditure, 2006
• Table 9.6 Watson Nephrology Product Portfolio
• Table 9.7 Watson Urology Product Portfolio
• Table 9.8 Pain Product Portfolio
• Table 9.9 Women' s Health Product Portfolio
• Table 9.10 Other Specialty Product Portfolio
• Table 9.11 Watson Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Table 10.1 Actavis Total Revenue ($m) and Net Profit ($m), 2006
• Table 10.2 Actavis Leading Products in Major Markets, 2006
• Table 10.3 Actavis Revenue ($m) in Key Regions, 2006
• Table 10.4 Actavis Watson Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Table 11.1 Barr Total Revenues and Net Earnings, 2003-2006
• Table 11.2 Comparison of the six months ended December 31 2006 and December 31, 2005
• Table 11.3 Barr Leading Products, 2006
• Table 13.4 Total Revenue of Oral Contraceptive, 2004-2006
• Table 13.5 Barr Patent Challenges and Valuation
• Table 11.6 Barr Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Table 11.7 Total Revenue of Proprietary Products, 2004-2006
• Table 11.8 Total Revenue of Proprietary Products, 2004-2006
• Table 12.1 Total Revenue ($m), Net Income ($m) and Operating Profit ($m), 2003-2006
• Table 12.2 Stada Core Business Revenues, 2006
• Table 12.3 Regional Sales Distribution, 2003-2006
• Table 12.4 Stada US Revenue ($m), 2002-2006
• Table 12.5 Regional Sales Distribution, 2003-2006
• Table 12.6 Revenues in Leading EU Markets, 2006
• Table 12.7 Revenue in Five Leading EU Markets, 2006
• Table 12.8 Revenue in Other Leading EU Markets, 2006
• Table 12.9 Revenue Top Five Leading Generic Products, 2006
• Table 12.10 Stada Top Five Branded Products Division Revenue, 2006
• Table 12.11 Stada Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Table 12.12 Stada M&A Operations, 2006
• Table 12.13 Stada M&A Operations, 2006
• Table 13.1 Total Revenue ($m) and Profit ($m) for Mylan
• Table 13.2 Total Revenue ($m) of Mylan Leading Therapeutic Classes
• Table 13.3 Mylan' s Leading Products, 2006
• Table 13.4 Mylan Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Table 13.5 Mylan' s R&D Investment, 2003-2007
• Table 14.1 Apotex Revenues, 2004-2007
• Table 14.2, Market Share of Apotex Leading Therapeutic Classes, 2006
• Table 14.3 Apotex Geographical Revenues, 2006
• Table 14.4 Apotex Revenues in US and Canada, 2006
• Table 14.5 Apotex Revenues in Key EU Markets, 2006
• Table 14.6 Apotex Revenues in Key Latin American Markets, 2006
• Table 14.7 Apotex Revenues in Key Central American Markets, 2006
• Table 14.8 Apotex Revenues in Key Africa, Asia& Australia Markets, 2006
• Table 14.9 Apotex Revenues For Leading Drugs, 2006
• Table 14.10 Apotex Revenues For Top Five Drugs, 2006
• Table 14.11 Apotex Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Table 15.1 Near-term Patent Expiration ,207-2009

List of Figures

• Figure 1.1 Top 10 Generic Comapnies, Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Figure 2.1 Sales 2004-2006 All Companies: Total Group Sales
• Figure 2.2 Market Share of Sales of All Companies: Total Group Sales,2006
• Figure 2.3 The Leading Generics Companies: Total Generic Sales Only, 2005-2006
• Figure 2.4 Market Share of Sales of All Companies: Generic Sales Only, 2006
• Figure 3.1 Per Capita Growth Rate for National Health Expenditure Vs Prescription Drugs Over Four Decades
• Figure 5.1 Teva Net Sales, 2006
• Figure 5.2 Teva Net Income, 2006
• Figure 5.3 Sales ($m) by Geographical Area, 2004-2006
• Figure 5.4 Sales ($m) by Business Division, 2004-2006
• Figure 5.5 Teva Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Figure 5.6 R&D Investment by Teva, 2002-2006
• Figure 6.1 Sandoz Net Sales ($m) and Other Key Financials, 2006
• Figure 6.2 Sandoz Net Sales (%) by Region, 2006
• Figure 6.3 Sandoz Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Figure 7.1 Sales of Pharmaceutical and Chemical Division, 2002-2006
• Figure 7.2 Revenues of Pharmaceutical Businesses, 2002-2006
• Figure 7.3 Market Share of Merck KGaA Businesses, 2006
• Figure 7.4 Regional Revenues of Generic Pharmaceuticals, 2006
• Figure 7.5 Regional Market Share of Generic Pharmaceuticals, 2006
• Figure 7.6 Merck KGaA Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Figure 8.1 Market Share of Ratiopharm Top Ten Selling Therapeutic Classes,2006
• Figure 8.2 Market Share of Ratiopharm Top Ten Selling Generics, 2006
• Figure 8.3 Regional Sale Distribution, 2006
• Figure 8.4 Sales Distribution in Major EU Markets, 2006
• Figure 8.5 Sales Distribution in Canada and the US, 2006
• Figure 8.6 Sales Distribution in Africa, Asia and Australian Markets, 2006
• Figure 8.7 Market Share Distribution in Latin American Markets, 2006
• Figure 8.8 Ratiopharm Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Figure 9.1 Total Revenue Including Major Operations, 2006
• Figure 9.2 Net Revenue In Comparison With Other Operational Losses, 2006
• Figure 9.3 Market Share of Branded Products Vs Generics
• Figure 9.4 Watson' s R&D Expenditure, 2002-2006
• Figure 9.5 Generic Segment Sales, 2006
• Figure 9.6 Revenues of Branded Products Operations,2006
• Figure 9.7 R&D and Other Operating Expenditure, 2006
• Figure 9.8 Watson Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Figure 9.9 Watson ANDA Submission, 2002-2006
• Figure 9.10 Watson ANDA Pending Approvals 2002-2006
• Figure 10.1 Actavis Total Revenue ($m) and Net Profit ($m), 2006
• Figure 10.2 Actavis Regional Market Share Distribution
• Figure 10.3 Market Share of Actavis Leading Products in Major Markets, 2006
• Figure 10.4 Actavis Revenue ($m) in Key Regions, 2006
• Figure 10.5 Actavis Market Share in CEEA Market 2006
• Figure 10.6 Actavis Market Share in WEMEA Market, 2006
• Figure 10.7 Actavis Third Party Division Market Share Market, 2006
• Figure 10.8 Actavis Third Party Division Regional Market Share Market, 2006
• Figure 10.9 Actavis Watson Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Figure 11.1 Barr Total Revenues and Net Earnings, 2003-2006
• Figure 11.2 Barr Leading Products, 2006
• Figure 11.3 Total Revenue of Oral Contraceptive, 2004-2006
• Figure 11.4 Barr Generic Products Revenues ($bn) Forecast, 2008-2013, 2018 & 2023
• Figure 11.5 Total Revenue of Proprietary Products, 2004-2006
• Figure 11.6 Total Revenue of Proprietary Products, 2004-2006
• Figure 12.1 Net Income ($m) and Operating Profit ($m), 2003-2006
• Figure 12.2 Stada Core Business Revenues, 2006
• Figure 12.3 Market Share of Stada Core Business Revenues, 2006
• Figure 12.4 Regional Sales Distribution, 2003-2006
• Figure 12.5 Market share of Regional Sales Distribution, 2006
• Figure 12.6 Stada US Revenue ($m), 2002-2006
• Figure 12.7 Stada Market Share in Six Major Regions, 2006
• Figure 12.8 Market Share Revenues in Leading EU Markets, 2006
• Figure 12.9 Revenue in Five Leading EU Markets, 2006
• Figure 12.10 Revenue in Other Leading EU Markets, 2006
• Figure 12.11 Stada Generic Division Revenue, 2003-2006
• Figure 12.12 Revenue Top Five Generic Products, 2006
• Figure 12.13 Stada Branded Products Division Revenue, 2003-2006
• Figure 12.14 Market Share of Stada' s Top Five Branded Products Division Revenue, 2006
• Figure 12.15 Stada Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Figure 12.16 Stada M&A Operations, 2006
• Figure 12.17 Stada M&A Disposals Revenue, 2006
• Figure 13.1 Mylan Total Revenue ($m) and Profit ($m),2003-2006
• Figure 13.2 Total Revenue ($m) of Mylan Leading Therapeutic Classes
• Figure 13.3 Market Share Distribution of Mylan' s Leading Therapeutic Classes
• Figure 13.4 Total Revenue Distribution in Major Geographical markets, 2006
• Figure 13.5 Market Share of Mylan' s Leading Products, 2006
• Figure 13.6 Mylan Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Figure 13.7 Mylan' s R&D Investment, 2003-2007
• Figure 14.1 Apotex Revenues, 2004-2007
• Figure 14.2 Market Share of Apotex Leading Therapeutic Classes, 2006
• Figure 14.3 Apotex Geographical Revenues, 2006
• Figure 14.4 Market Share of Apotex Revenues in US and Canada, 2006
• Figure 14.5 Market Share of Apotex Revenues in Key EU Markets, 2006
• Figure 14.6 Market Share of Apotex Revenues in Key Latin American Markets, 2006
• Figure 14.7 Apotex Revenues in Key Central American Markets, 2006
• Figure 14.8 Market Share of Apotex Revenues in Key Africa, Asia & Australia Markets, 2006
• Figure 14.9 Apotex Revenues For Leading Drugs, 2006
• Figure 14.10 Apotex Revenues For Top Five Drugs, 2006
• Figure 14.11 Apotex Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023

Companies mentioned in this report:

• Abbott Laboratories
• Abrika
• Abz Pharma
• Actavis
• Active Biotech
• Akzo Nobel
• Alcon Labs
• Allergan
• Alphapharm
• Alza
• Amgen
• Amide
• Anchen Pharmaceuticals
• Andrx
• Apotex
• Apothecon
• AstraZeneca
• Aventis
• Azupharma
• Balkanpharma
• BASF Pharma
• Bayer
• Bioceuticals Arzneitmittel
• Biochemie
• Biogen Idec
• Bioval
• Boehringer Ingelheim
• Bristol- Myers Squibb
• Cajavec
• Cell Pharma
• Celltech
• Cephalon
• Cipla
• Colotech
• Croma
• CT Arzneimittel
• Daiikyi Sankyo
• Dey
• Duramed
• Durascan
• Eisai
• Elan
• Eli Lilly
• Elite
• Eon Labs
• Esteve Quimica S.A
• Eurogenerics
• FEI Women' s Health LLC
• Ferd Schulze
• Forum Bioscience
• Geneva Pharmaceuticals
• Genevar
• Genpharm
• GlaxoSmithKline
• GlycoSciences
• Helvepharm
• Hemovet
• Hexal AG
• Hospira
• IMPAX
• IntelliPharmaCeutics
• Ivax
• Janssen
• Johnson & Johnson
• King Pharmaceuticals
• Labinca
• Lagap Pharmaceuticals
• Lareq Pharma
• Lundbeck
• Magnafarma BV
• Markiz
• Martec
• Matrix Docpharma
• Matrix Laboratories
• Meph
• Merck & Co
• Merck Génériques
• Merck KGaA
• Merckle
• Multipharma
• Mylan
• Mylan Technologies Inc
• NM Pharma
• Nycomed
• Organon
• Ortho Biotech
• ParaGard
• Penederm
• Pfizer
• Pharmacia
• PharmaCoDane Aps
• Plantex
• Pliva
• PriceWaterHouseCooper
• Proctor & Gamble
• Progen Biotechnik
• Quimica Farmaceutica
• Ratiopharm
• Roche
• Rolab
• Sabex
• Sandoz
• Sanmar
• Sanofi-Aventis
• Savient
• Scandharm
• Schering-Plough
• Sekhsaria Chemical Limited
• Serono
• Servipharm
• Shire
• Sigma
• Sindan
• Solvay
• Somerset Pharma
• Stada
• Takeda
• Technilab Pharma
• Teva
• Topgen
• UCB
• UDL Laboratories
• US Department of Defence
• Ventiv Health
• Warner Chilcott
• Watson
• Weizmann Institute of Science
• WHO
• Wyeth
• Xanodyne
• Zambon
• Zio Zdorovje

相關商品